<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300156</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-10-524</org_study_id>
    <nct_id>NCT01300156</nct_id>
  </id_info>
  <brief_title>Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)</brief_title>
  <official_title>A Multicenter Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Patients With Refractory or Relapsed Hodgkin's Lymphoma (HL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of combination chemotherapy
      with etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin (ESHAOx) for
      patients with refractory or relapsed Hodgkin's lymphoma (HL).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response rate to ESHAOx chemotherapy</measure>
    <time_frame>within 3 weeks after the completion of the treatment</time_frame>
    <description>To evaluate response rate by Cheson criteria for malignant lymphoma after 3 and 6 cycles of treatment with ESHAOx regimen in patients with refractory or relapsed Hodgkin's lymphoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, response duration, toxicity profiles</measure>
    <time_frame>up to 5 years after the completion of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>ESHAOx arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are planned to be treated with ESHAOx chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin-based chemotherapy (ESHAOx)</intervention_name>
    <description>Etoposide 40 mg/m2, D1-4
Methylprednisolone 500mg, D1-5
Cytarabine 2 g/m2, D5
Oxaliplatin 130 mg/m2, D1</description>
    <arm_group_label>ESHAOx arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously histologically confirmed Hodgkin's lymphoma

          -  Failure to achieve a complete remission with the initial induction chemotherapy, or
             recurrent disease

          -  Performance status (ECOG) ≤ 3

          -  Age ≤ 75 years old

          -  Number of prior chemotherapies: one or two regimens

          -  At least one or more uni-dimensionally measurable lesion(s) defined as; ≥ 2 cm by
             conventional CT or ≥ 1 cm by spiral CT or skin lesion (photographs should be taken) or
             measurable lesion by physical examination

          -  Adequate organ functions defined as; ANC &gt; 1,500/ul, platelet &gt; 75,000/ul,
             transaminases &lt; 3 X upper normal values; bilirubin &lt; 2 mg/dL

          -  Written informed consent approved by institutional review board or ethic committee

        Exclusion Criteria:

          -  Previous high dose chemotherapy with autologous stem cell transplantation or
             allogeneic stem cell transplantation

          -  Previous chemotherapies with ESHAP regimen

          -  Any other malignancies within the past 5 years except skin basal cell carcinoma or
             carcinoma in situ of cervix

          -  Other serious illness or medical conditions

          -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months
             prior to study entry

          -  History of significant neurologic or psychiatric disorders including dementia or
             seizures

          -  Active uncontrolled infection (viral, bacterial or fungal infection)

          -  Other serious medical illnesses

          -  Pregnancy or breast-feeding, women of childbearing potential not employing adequate
             contraception

          -  Previous history of drug allergy to one of the drugs in the study regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon Seok Eom, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyewon Lee, MD</last_name>
    <phone>+82-31-920-1765</phone>
    <email>hwlee@ncc.re.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyewon Lee, MD</last_name>
      <phone>+82-31-920-1765</phone>
      <email>hwlee@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Hyeon Seok Eom, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hyeon-Seok Eom / MD, PhD</name_title>
    <organization>Natioinal Cancer Center, Korea</organization>
  </responsible_party>
  <keyword>Hodgkin's disease</keyword>
  <keyword>lymphoma</keyword>
  <keyword>Relapsed</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

